Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts
Dr. Ghobrial is a Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School and the Lavine Family Chair for Preventative Cancer Therapies. She is also an Associate Member of the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard. She is the Director of the Clinical Investigator Research Program at DFCI, Director of Translational Research in the Department of Multiple Myeloma, and Director of the Center for Prevention of Progression diseases (CPOP) and co-leader of the Dana-Farber Harvard Cancer Center Lymphoma and Myeloma Program. She is the recipient of the Kyle Award for Waldenstrom, the Ken Anderson Young Investigator Award and the Mentor of the year award at DFCI.
Her laboratory and clinical studies thus focus on identifying and developing effective therapeutic interventions for precursor conditions of myeloma (Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, MGUS and SMM). This can only be achieved by defining genomic and epigenomic markers that are associated with disease progression, microenvironmental changes that affect tumor progression to myeloma, and mechanisms of immune evasion in disease progression. The focus of her research is to identify novel biomarkers of disease progression and help develop potentially curative therapies in the pre-malignant phase that exploit the immune microenvironment in the bone marrow. She developed a large, patient-empowering observational study for these precursor conditions (the PCROWD study) and recruited over 3,000 patients,. She is also the PI of the first screening study for multiple myeloma in the US, the PROMISE study.